Zydus Lifesciences · NSE: ZYDUSLIFE · BSE: 532321

Q1 FY24 results · Apr–Jun 2023

Zydus Lifesciences reported revenue from operations of ₹5,139.60 crore (up 26.2% from Q1 FY23) and net profit of ₹1,133.60 crore (up 96.7% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY24	Q1 FY23	YoY	Q4 FY23	QoQ
Revenue from operations	5,139.60	4,072.70	+26.2%	5,010.60	+2.6%
Other income	36.00	65.90	−45.4%	37.80	−4.8%
Total income	5,175.60	4,138.60	+25.1%	5,048.40	+2.5%
Profit before share of associates & JVs and tax	1,329.20	681.00	+95.2%	485.80	+173.6%
Share of profit/(loss) of associates & JVs	21.50	22.10		11.80
Net profit for the period	1,133.60	576.40	+96.7%	358.20	+216.5%
Attributable to shareholders of the company	1,086.90	518.30	+109.7%	296.60	+266.5%
EPS, basic (₹)	10.74	5.06	+112.3%	2.93	+266.6%
Net margin (%)	22.1	14.2		7.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY24	Q1 FY23	YoY	Q4 FY23	QoQ
Revenue from operations	2,955.70	1,980.90	+49.2%	2,579.30	+14.6%
Other income	82.40	51.70	+59.4%	251.20	−67.2%
Total income	3,038.10	2,032.60	+49.5%	2,830.50	+7.3%
Profit before tax	1,012.50	432.30	+134.2%	615.00	+64.6%
Net profit for the period	780.90	331.50	+135.6%	490.70	+59.1%
EPS, basic (₹)	7.71	3.24	+138.0%	4.85	+59.0%
Net margin (%)	26.4	16.7		19.0

Consolidated

Filed with BSE: 11 Aug 2023, 15:27 IST
Board meeting: 11 Aug 2023
Period: 01 Apr 2023 to 30 Jun 2023
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 11 Aug 2023, 15:27 IST
Board meeting: 11 Aug 2023
Period: 01 Apr 2023 to 30 Jun 2023
Review status: Unaudited
Source: XBRL filing on BSE